News from sorrento therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 08, 2014, 09:00 ET

Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com), a late-stage clinical oncology company developing new...

Dec 19, 2013, 19:10 ET

Sorrento Therapeutics Completes Acquisition of Concortis Biosystems

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has completed its acquisition of Concortis Biosystems, Corp.,...

Nov 14, 2013, 07:00 ET

Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today the entry into a definitive agreement to acquire San Diego-based Concortis...

Nov 12, 2013, 08:00 ET

Sorrento Therapeutics Adopts Stockholder Rights Plan

Sorrento Therapeutics,  Inc. (NASDAQ: SRNE) announced that its Board of Directors adopted a stockholder rights plan (the "Rights Plan" or...

Nov 05, 2013, 08:00 ET

Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has entered into an antibody and vaccine development...

Oct 30, 2013, 14:07 ET

Sorrento Therapeutics Announces Closing of Public Offering of Common Stock

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) today announced the closing of its previously announced underwritten public offering.  The...

Oct 25, 2013, 16:10 ET

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the  full exercise of the over-allotment option granted to the underwriters to...

Oct 24, 2013, 20:29 ET

Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an...

Oct 10, 2013, 19:15 ET

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain

Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has acquired Sherrington Pharmaceuticals, Inc. (Sherrington), a...

Sep 16, 2013, 08:00 ET

Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: From Concept to Clinic

 Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today it will present the clinical data for Cynviloq™ (IG-001), which...

Sep 10, 2013, 08:15 ET

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy

 Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has secured an option to an exclusive license for the worldwide...

Sep 10, 2013, 08:00 ET

Sorrento Therapeutics Completes IgDraSol Merger

 Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has completed the merger with IgDraSol, Inc., a privately-held...

Sep 06, 2013, 08:00 ET

Sorrento Therapeutics to Present at Two Healthcare Conferences

Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that Dr. Henry Ji, President and CEO, will present a corporate overview at two...

Aug 05, 2013, 08:00 ET

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway

 Sorrento Therapeutics, Inc. (OTCQB: SRNE; SRNED; Sorrento) and IGDRASOL announced today that IGDRASOL has received official meeting minutes...

Aug 01, 2013, 08:00 ET

Sorrento Therapeutics Announces Reverse Split of Common Stock

Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that it has filed a Certificate of Amendment to its Restated Certificate...

Jul 09, 2013, 09:00 ET

Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies

Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. announced today that they have entered...

Jul 01, 2013, 09:00 ET

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia

Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present Phase III interim data analysis of...

Jun 24, 2013, 06:00 ET

Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit

 Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that preclinical data of its therapeutic fully human anti-PD-L1 and...

Jun 21, 2013, 05:00 ET
Jun 06, 2013, 05:00 ET

Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology

 Sorrento Therapeutics, Inc. (OTCBB: SRNE) today announced that it has been awarded the 2013 Frost & Sullivan Global Investment Opportunity...